항균제 감수성 시험 시장 : 전략적 인사이트와 예측(2026-2035년)

The Antimicrobial Susceptibility Testing Market is set to reach USD 12.03 billion in 2035, growing at a CAGR of 8.8% from USD 5.63 billion in 2026.

The antimicrobial susceptibility testing market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance and the global imperative for responsible antibiotic stewardship. The market's evolution is characterized by a shift from traditional manual methods toward advanced automated systems and rapid molecular diagnostics that deliver faster, more standardized results. Healthcare systems are increasingly adopting automated AST platforms to improve workflow efficiency, reduce turnaround times, and enhance diagnostic accuracy in clinical microbiology. The rising prevalence of multidrug-resistant pathogens is creating sustained demand for rapid and accurate susceptibility testing to support targeted antibiotic therapy and improve patient outcomes. National antimicrobial stewardship programs and global initiatives led by organizations such as the WHO and CDC are encouraging wider implementation of AST, strengthening market growth worldwide. The convergence of laboratory automation, artificial intelligence, and digital microbiology is enabling more efficient management of increasing testing volumes across hospital microbiology laboratories, diagnostic centers, and public health institutions. The market is witnessing significant investment in rapid molecular resistance detection technologies, AI-powered result interpretation, and integrated laboratory information systems, positioning AST as a critical component of modern infectious disease management.

Market Drivers

The increasing prevalence of multidrug-resistant pathogens represents the primary driver for the antimicrobial susceptibility testing market. Healthcare providers are adopting advanced AST systems to support targeted antibiotic therapy and improve patient outcomes. The growing burden of antimicrobial resistance is creating sustained demand for rapid and accurate susceptibility testing across clinical, public health, and pharmaceutical settings. The rising number of bacterial, fungal, and healthcare-associated infections has increased the need for timely pathogen identification and susceptibility testing. This trend is expanding the utilization of AST across hospitals, diagnostic laboratories, and public health institutions. Clinical laboratories are investing in automated AST platforms to improve workflow efficiency, reduce turnaround time, and enhance diagnostic accuracy. Laboratory automation is becoming a key growth driver, particularly in high-volume healthcare facilities where standardized testing is essential for effective antimicrobial stewardship. National antimicrobial stewardship programs and global initiatives are encouraging wider implementation of antimicrobial susceptibility testing. Strengthened regulatory oversight, public health surveillance systems, and funding for antimicrobial resistance research continue to accelerate the adoption of AST technologies across diverse healthcare systems.

Market Restraints

Automated susceptibility testing instruments and molecular diagnostic platforms require significant capital investment, limiting adoption among small and medium-sized laboratories. The substantial upfront costs for equipment and infrastructure create barriers for facilities in resource-constrained settings. Operation of advanced microbiology analyzers requires trained personnel with expertise in microbiology, molecular diagnostics, and laboratory automation, creating workforce challenges in many regions. The shortage of qualified professionals limits the scalability of AST services. Strict regulatory requirements for in vitro diagnostic devices increase product development timelines and commercialization costs, delaying market entry for innovative technologies. The rigorous approval processes create challenges for smaller diagnostic manufacturers. Many low- and middle-income countries lack adequate laboratory infrastructure, funding, and diagnostic capacity, restricting widespread implementation of advanced AST technologies. These infrastructure gaps limit market penetration in regions with the highest burden of infectious diseases.

Technology and Segment Insights

The technology landscape is characterized by the growing dominance of automated susceptibility testing systems. Automated AST provides standardized, reproducible, and rapid antimicrobial susceptibility results with minimal manual intervention. Large hospitals and reference laboratories increasingly prefer automated systems to improve laboratory efficiency and reduce turnaround times. Rapid molecular methods are experiencing the fastest growth because they enable early detection of antimicrobial resistance genes and significantly reduce diagnostic turnaround times. Broth microdilution remains the reference standard because it provides highly accurate minimum inhibitory concentration determination and supports standardized clinical decision-making. Disk diffusion continues to be widely used owing to its simplicity, affordability, and extensive clinical acceptance. Gradient diffusion methods provide quantitative MIC values while maintaining operational flexibility for routine laboratories. The segment analysis reveals that reagents and consumables account for the largest share because AST procedures require continuous use of susceptibility panels, culture media, antimicrobial disks, broth reagents, quality control materials, and testing kits. Instruments generate significant capital revenue through automated AST analyzers and integrated microbiology platforms. Software adoption is increasing as laboratories implement digital workflow management, automated result interpretation, antimicrobial stewardship support, and laboratory information management systems. Clinical diagnostics represent the leading application segment, with hospital microbiology laboratories remaining the largest end users. Pharmaceutical and biotechnology companies are increasingly adopting AST in drug discovery and development. Epidemiological surveillance and veterinary diagnostics are expanding applications, driven by growing antimicrobial resistance monitoring needs.

Competitive and Strategic Outlook

The competitive landscape features established microbiology diagnostics companies alongside specialized molecular testing providers. bioMerieux is a global leader through its VITEK platform, automated microbiology systems, and antimicrobial stewardship solutions, continuing to expand its microbiology portfolio through continuous innovation. Becton, Dickinson and Company provides comprehensive microbiology laboratory solutions, including automated identification and susceptibility testing systems, specimen management technologies, and antimicrobial resistance surveillance platforms. Thermo Fisher Scientific offers microbiology reagents, molecular diagnostics, sequencing technologies, laboratory automation solutions, and antimicrobial susceptibility testing products supporting clinical laboratories worldwide. Danaher, through Beckman Coulter, develops laboratory automation and diagnostic workflow solutions that enhance microbiology laboratory productivity. Bruker continues expanding its MALDI-TOF-based microbiology solutions by integrating rapid organism identification with antimicrobial susceptibility testing workflows. QIAGEN specializes in molecular diagnostics, syndromic testing, and antimicrobial resistance gene detection technologies supporting rapid susceptibility testing. Bio-Rad develops molecular diagnostic assays, quality control products, and laboratory systems supporting infectious disease diagnostics. Accelerate Diagnostics focuses on rapid pathogen identification and phenotypic antimicrobial susceptibility testing technologies that significantly reduce time-to-result. Companies are pursuing product portfolio expansion through innovation in automated AST platforms, rapid molecular resistance detection, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and healthcare systems are increasing, driven by the need for antimicrobial stewardship and resistance surveillance. Recent key developments include bioMerieux expanding its VITEK automated microbiology platform with enhanced antimicrobial susceptibility testing capabilities. BD introduced workflow improvements for automated microbiology laboratories aimed at strengthening antimicrobial stewardship initiatives. Thermo Fisher Scientific expanded its clinical microbiology portfolio through new molecular diagnostic solutions for antimicrobial resistance detection. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The antimicrobial susceptibility testing market is positioned for sustained growth driven by the convergence of rising antimicrobial resistance, laboratory automation, and global stewardship initiatives. The transition from manual methods toward automated and molecular AST platforms represents a fundamental shift in clinical microbiology. While challenges related to capital investment, workforce shortages, and regulatory complexity persist, strategic investments in technology, innovation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with antimicrobial susceptibility testing evolving into an essential component of precision infectious disease management, supporting targeted antibiotic therapy, resistance surveillance, and public health initiatives worldwide.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Antimicrobial Susceptibility Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Antimicrobial Resistance (AMR) Burden Analysis
• 3.8 Testing Volume Analysis
• 3.9 Laboratory Workflow Analysis
• 3.10 Clinical Significance of Antimicrobial Susceptibility Testing

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Diagnostic Pipeline Analysis
• 6.4 Automation in Antimicrobial Susceptibility Testing
• 6.5 Artificial Intelligence and Data Analytics Integration
• 6.6 Digital Microbiology and Laboratory Informatics
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Antimicrobial Susceptibility Testing Market Landscape Analysis

• 8.1 Analysis by Product Type
  • 8.1.1 Instruments
  • 8.1.2 Reagents & Consumables
  • 8.1.3 Software
• 8.2 Analysis by Technology Platform
  • 8.2.1 Automated AST Systems
  • 8.2.2 Manual AST Methods
  • 8.2.3 Molecular AST Methods
  • 8.2.4 Broth Microdilution
  • 8.2.5 Disk Diffusion
  • 8.2.6 Gradient Diffusion (E-test)
• 8.3 Analysis by Sample Type
  • 8.3.1 Blood
  • 8.3.2 Urine
  • 8.3.3 Respiratory Samples
  • 8.3.4 Wound Samples
  • 8.3.5 Other Clinical Samples
• 8.4 Analysis by Application
  • 8.4.1 Clinical Diagnostics
  • 8.4.2 Pharmaceutical Research
  • 8.4.3 Food Safety Testing
  • 8.4.4 Veterinary Diagnostics

9. Global Antimicrobial Susceptibility Testing Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software
• 9.2 By Method
  • 9.2.1 Automated Susceptibility Testing
  • 9.2.2 Manual Susceptibility Testing
• 9.3 By Technology
  • 9.3.1 Broth Microdilution
  • 9.3.2 Disk Diffusion
  • 9.3.3 Gradient Diffusion
  • 9.3.4 Rapid Molecular Methods
  • 9.3.5 Other Technologies
• 9.4 By Application
  • 9.4.1 Clinical Diagnostics
  • 9.4.2 Drug Discovery & Development
  • 9.4.3 Epidemiological Surveillance
  • 9.4.4 Food & Beverage Testing
  • 9.4.5 Veterinary Diagnostics
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Pharmaceutical & Biotechnology Companies
  • 9.5.4 Academic & Research Institutes
  • 9.5.5 Food Testing Laboratories
  • 9.5.6 Veterinary Laboratories

10. Global Antimicrobial Susceptibility Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Antimicrobial Susceptibility Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Mexico
• 11.16 Saudi Arabia
• 11.17 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 bioMerieux
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Becton, Dickinson and Company
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Thermo Fisher Scientific Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 Danaher Corporation
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 Bruker Corporation
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 QIAGEN N.V.
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 Bio-Rad Laboratories, Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 Accelerate Diagnostics, Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Beckman Coulter, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 Merlin Diagnostika GmbH
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 Hardy Diagnostics
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Liofilchem S.r.l.
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 HiMedia Laboratories Pvt. Ltd.
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 Creative Diagnostics
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 Mast Group Ltd.
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Antimicrobial Susceptibility Testing Market Commercial Forecast Analysis

• 14.1 Automated AST Systems
• 14.2 Manual AST Systems
• 14.3 Broth Microdilution Products
• 14.4 Disk Diffusion Products
• 14.5 Gradient Diffusion Products
• 14.6 Molecular AST Platforms
• 14.7 AST Reagents & Consumables
• 14.8 Laboratory Software Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends